molsidomine has been researched along with Fibrosis in 4 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies." | 7.79 | The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013) |
| "NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 7.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
| "Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart." | 3.85 | Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017) |
| " We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies." | 3.79 | The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013) |
| "• To investigate whether sustained long-term separate treatments of diabetic inducible nitric oxide synthase knockout (iNOSKo) mice with allopurinol, an antioxidant inhibiting xanthine oxidoreductase, decorin, a transforming growth factor-β1 (TGFβ1) -binding antagonist, and molsidomine, a long-life nitric oxide donor, prevent the processes of diabetes-induced cavernosal fibrosis." | 3.78 | Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice. ( Ferrini, MG; Gonzalez-Cadavid, NF; Moon, J; Rajfer, J; Rivera, S, 2012) |
| "NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 3.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zordan, P | 1 |
| Sciorati, C | 1 |
| Campana, L | 1 |
| Cottone, L | 1 |
| Clementi, E | 1 |
| Querini, PR | 1 |
| Brunelli, S | 1 |
| Oosterhuis, NR | 1 |
| Bongartz, LG | 1 |
| Verhaar, MC | 1 |
| Cheng, C | 1 |
| Xu, YJ | 1 |
| van Koppen, A | 1 |
| Cramer, MJ | 1 |
| Goldschmeding, R | 1 |
| Gaillard, CA | 1 |
| Doevendans, PA | 1 |
| Braam, B | 1 |
| Joles, JA | 1 |
| Ferrini, MG | 1 |
| Moon, J | 1 |
| Rivera, S | 1 |
| Rajfer, J | 1 |
| Gonzalez-Cadavid, NF | 1 |
| Peters, H | 1 |
| Daig, U | 1 |
| Martini, S | 1 |
| Rückert, M | 1 |
| Schäper, F | 1 |
| Liefeldt, L | 1 |
| Krämer, S | 1 |
| Neumayer, HH | 1 |
4 other studies available for molsidomine and Fibrosis
| Article | Year |
|---|---|
The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy.
Topics: Animals; Disease Models, Animal; Fibrosis; Humans; Immunity, Innate; Inflammation; Mice; Molsidomine | 2013 |
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess | 2017 |
Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.
Topics: Allopurinol; Animals; Antioxidants; Apoptosis; Decorin; Diabetes Mellitus, Experimental; Enzyme Inhi | 2012 |
NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Enzyme Inhibitors; Fibronectins; Fibrosis; Gene Expr | 2003 |